Welcome to another posting of ‘Industry Insight with Chester,’ a periodic round-up of news and views from around the Pharma and biopharma industries compiled by Chester Solack, Business Analyst at SAFC in Lenexa, Kansas.
Archive for the ‘Bioconjugation’ Category
Industry Insight with Chester: A Collection of Current Industry Updates
Friday, May 18th, 2012Contract Pharma Outsourcing Survey 2012
Tuesday, May 15th, 2012Contract Pharma recently released their annual Outsourcing Survey where the publication takes time to poll players in the pharma industry on hot button outsourcing topics. The survey is broken out by size of company, specialty of company and title of the responders and as a whole, it offers exceptional insight into the current landscape of outsourcing and upcoming trends. The full report can be found by clicking here.
BREAKING NEWS: Sigma-Aldrich Acquires Research Organics to Strengthen Portfolio of PharmaGrade Raw Materials
Tuesday, April 3rd, 2012Yesterday, Sigma-Aldrich announced the acquisition of Research Organics, a leading supplier of biochemicals for use in various bioprocessing, biotechnology and diagnostic applications. The addition means that SAFC will now be able to offer dual sourced buffers, as well as an expansion of the raw materials catalog of products. As executives for both companies noted, the acquisition has been made with an end goal of increasing quality of service and capacity to partner with customers on both standard and custom project solutions.
To read the full press release, please click below. To learn more about SAFC’s line of PharmaGrade Products, please click here.
SAFC Presents at the Upcoming ICH Q3D Metal Impurities Workshop in Bethesda, Maryland
Monday, April 2nd, 2012From April 4-5, 2012, delegates will gather at the Marriott Bethesda North Hotel in Bethesda, Maryland for the two day ICH Q3D Metal Impurities Workshop that will feature a program focused on the new limits for element impurities in drug products and how they may impact businesses in the pharma industry.
On Wednesday, April 4th at 9am, SAFC Quality Assurance Director, Patty Benson, will participate in a panel titled “Perspectives From Active Pharmaceutical Ingredient (API) Suppliers”, along with a lineup of speakers from industry colleagues, the IPEC-Americas, CHPA and SOCMA’s Bulk Pharmaceutical Task Force (BPTF) to discuss the draft guidelines and implications data will have, as well as the impact on pharmaceuticals. Patty’s input from an API maker’s perspective will be complemented with an excipient user perspective from Janeen Skutnik-Wilkinson, Director of Quality and Regulatory Policy at Pfizer Inc. and an excipient maker perspective from David Schoneker, Director of Global Regulatory Affairs at Colorcon.
We hope to see you there to learn, network and exchange information amongst industry peers. To learn more about registration for the event, please click here. To learn more about SAFC, please click here.
SAFC Offers Insight into ADCs for the Present and the Future
Thursday, February 9th, 2012SAFC is just a few days away from arriving in New Orleans for Informex 2012. As an exhibitor and sponsor of the Informex Networking Lounge, SAFC will have various members of the executive and sales team onsite to discuss SAFC capabilities and technologies. In particular, SAFC will be available to discuss their capabilities surrounding the creation of antibody – drug conjugates (ADCs) which have recently received a lot of press as they become more relevant to the chemical and pharma industry.
Because of their potency, ADCs require a different level of manufacturing capabilities, and SAFC is one of a handful of companies that has made large investments in GMP manufacturing capabilities for antibody – drug conjugates. Here, SAFC Process Development Manager, Michael Bienkowski, talks to us about the ADC market and future prospects for SAFC in this area.
An In-Depth Interview with SafeBridge President and CEO, John Farris
Friday, November 4th, 2011SAFC’s Verona plant has just been awarded SafeBridge Certification. But what does this mean, and what does the process involve? SafeBridge President and Chief Executive, John Farris, tells all in the following interview with SAFC Live.
Stellar Biotechnologies CEO, Frank Oakes, Discusses KLH Technology and Why They Partnered with SAFC
Tuesday, August 9th, 2011As promised, we return with a new perspective on the Stellar Biotechnologies and SAFC partnership. On August 3rd, Stellar announced SAFC as a partner for the supply of keyhole limpet hemocyanin (KLH), an important component of several vaccines that are in development. In this segment, Stellar President and Chief Executive Officer, Frank Oakes, explains how it produces KLH, and why the partnership is good for both companies.
